Axsome Therapeutics Files 8-K Report
Ticker: AXSM · Form: 8-K · Filed: Mar 19, 2024 · CIK: 1579428
| Field | Detail |
|---|---|
| Company | Axsome Therapeutics, INC. (AXSM) |
| Form Type | 8-K |
| Filed Date | Mar 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory-update
Related Tickers: AXSM
TL;DR
AXSM filed an 8-K, likely containing routine updates or exhibits. Keep an eye out for details.
AI Summary
On March 19, 2024, Axsome Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of other events and the inclusion of financial statements and exhibits. No specific material events or financial updates were detailed in the provided excerpt.
Why It Matters
This filing indicates Axsome Therapeutics is providing updates or submitting required documentation to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate disclosure of significant negative events.
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- March 19, 2024 (date) — Date of Report
- 0000950170-24-033148 (filing_id) — Accession Number
FAQ
What is the primary purpose of this 8-K filing for Axsome Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and to include 'Financial Statements and Exhibits' as of March 19, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is March 19, 2024.
What is Axsome Therapeutics, Inc.'s state of incorporation?
Axsome Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Axsome Therapeutics, Inc.?
The Commission File Number for Axsome Therapeutics, Inc. is 001-37635.
Where is Axsome Therapeutics, Inc.'s principal executive office located?
Axsome Therapeutics, Inc.'s principal executive office is located at One World Trade Center, 22nd Floor, New York, New York, 10007.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-03-19 07:06:01
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market
Filing Documents
- axsm-20240319.htm (8-K) — 39KB
- axsm-ex99_1.htm (EX-99.1) — 22KB
- img36028404_0.jpg (GRAPHIC) — 22KB
- 0000950170-24-033148.txt ( ) — 203KB
- axsm-20240319.xsd (EX-101.SCH) — 23KB
- axsm-20240319_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On March 19, 2024, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing that the first patient has been dosed in the PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol) Phase 3 trial of solriamfetol as an investigational treatment for major depressive disorder. The full text of the press release is filed as Exhibit 99.1 hereto, and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 19, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: March 19, 2024 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer